Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$6,442 Mln
P/E Ratio
--
P/B Ratio
123.68
Industry P/E
--
Debt to Equity
-0.01
ROE
-17.9 %
ROCE
100.82 %
Div. Yield
0 %
Book Value
--
EPS
-2.88
CFO
$-2,275.58 Mln
EBITDA
$-2,443.03 Mln
Net Profit
$-2,682.14 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
BridgeBio Pharma (BBIO)
| 24.56 | -1.70 | -5.27 | 38.16 | 50.58 | 4.87 | -- |
|
BSE Sensex
| 1.72 | 3.50 | 4.95 | 8.90 | 11.18 | 21.04 | 11.14 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
|
|---|---|---|---|---|---|
|
BridgeBio Pharma (BBIO)
| -31.81 | 429.79 | -54.32 | -76.54 | 102.88 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 61.50 | 11,346.08 | 26.77 | 8.05 | |
| 64.68 | 6,566.51 | 50.6 | 23.56 | |
| 57.38 | 11,265.03 | 388.07 | 0.76 | |
| 7.69 | 9,024.30 | -- | -3.24 |
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral... small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California. Address: 3160 Porter Drive, Palo Alto, CA, United States, 94304 Read more
Co-Founder, President, CEO & Director
Dr. Neil Kumar Ph.D.
Co-Founder, President, CEO & Director
Dr. Neil Kumar Ph.D.
Headquarters
Palo Alto, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of BridgeBio Pharma Inc (BBIO) stood at $ 919 Mln as on 31-Dec-24
The share price of BridgeBio Pharma Inc (BBIO) is $34.18 (NASDAQ) as of 22-Apr-2025 16:00 EDT. BridgeBio Pharma Inc (BBIO) has given a return of 50.58% in the last 3 years.
BridgeBio Pharma Inc (BBIO) has a market capitalisation of $ 6,442 Mln as on 21-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of BridgeBio Pharma Inc (BBIO) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the BridgeBio Pharma Inc (BBIO) and enter the required number of quantities and click on buy to purchase the shares of BridgeBio Pharma Inc (BBIO).
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California. Address: 3160 Porter Drive, Palo Alto, CA, United States, 94304
The CEO & director of Dr. Neil Kumar Ph.D.. is BridgeBio Pharma Inc (BBIO), and CFO & Sr. VP is Dr. Neil Kumar Ph.D..
There is no promoter pledging in BridgeBio Pharma Inc (BBIO).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,131
|
|
|
1,128
|
|
|
882
|
|
|
682
|
| BridgeBio Pharma Inc. (BBIO) | Ratios |
|---|---|
|
Return on equity(%)
|
38.11
|
|
Operating margin(%)
|
-199.59
|
|
Net Margin(%)
|
-241.44
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of BridgeBio Pharma Inc (BBIO) was $0 Mln.
$0.67
(
